Ipsen to buy liver disease drugmaker for $952M
Ipsen is set to acquire Albireo Pharma Inc., the rare liver disease-focused biopharma spun out of AstraZeneca in 2008, for about $952 million.
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Rowan Walrath Source Type: news
More News: AstraZeneca | Health Management | Liver | Liver Disease | Pharmaceuticals | Urology & Nephrology